Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.

Annals of internal medicine - 18 Feb 2014

Kazi Dhruv S, Garber Alan M, Shah Rashmee U, Dudley R Adams, Mell Matthew W, Rhee Ceron, Moshkevich Solomon, Boothroyd Derek B, Owens Douglas K, Hlatky Mark A

Abstract excerpt

BACKGROUND: The choice of antiplatelet therapy after acute coronary syndrome (ACS) is complicated: Ticagrelor and prasugrel are novel alternatives to clopidogrel, patients with some genotypes may not respond to clopidogrel, and low-cost generic formulations of clopidogrel are available. OBJECTIVE: To determine the most cost-effective strategy for dual antiplatelet therapy after percutaneous coronary intervention...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Coronary Syndrome
Share to Coronary Thrombosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Decision Support Techniques

Share to Percutaneous Coronary Intervention

Share to Prasugrel Hydrochloride

Share to Quality-Adjusted Life Years

Share to Thiophenes

Share to Ticagrelor

Source

Identifiers

PMID: 24727840
DOI: 10.7326/M13-1999

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cost-effectiveness of genotype-guided and dual antiplatelet therapies in acute coronary syndrome.PMID 24727840Read ↗

Genetic testing in patients with acute coronary syndrome undergoing percutaneous coronary intervention: a cost-effectiveness analysis.Semantic proximity Read ↗

Review of pharmacoeconomic evaluation of genotype-guided antiplatelet therapy.Semantic proximity Read ↗

Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel.Semantic proximity Read ↗

Ticagrelor versus genotype-driven antiplatelet therapy for secondary prevention after acute coronary syndrome: a cost-effectiveness analysis.Semantic proximity Read ↗

CYP2C19-guided antiplatelet therapy: a cost-effectiveness analysis of 30-day and 1-year outcomes following percutaneous coronary intervention.Semantic proximity Read ↗

CYP2C19 genotype plus platelet reactivity-guided antiplatelet therapy in acute coronary syndrome patients: a decision analysis.Semantic proximity Read ↗

Financial Analysis of CYP2C19 Genotyping in Patients Receiving Dual Antiplatelet Therapy Following Acute Coronary Syndrome and Percutaneous Coronary Intervention.Semantic proximity Read ↗

Cost-effectiveness of implementing a genotype-guided de-escalation strategy in patients with acute coronary syndrome.Semantic proximity Read ↗

A risk-benefit assessment of prasugrel, clopidogrel, and genotype-guided therapy in patients undergoing percutaneous coronary intervention.Semantic proximity Read ↗

Short- and long-term cost-effectiveness analysis of CYP2C19 genotype-guided therapy, universal clopidogrel, versus universal ticagrelor in post-percutaneous coronary intervention patients in Qatar.Semantic proximity Read ↗

Cost-effectiveness of CYP2C19-guided antiplatelet therapy for acute coronary syndromes in Singapore.Semantic proximity Read ↗

Cost-effectiveness of using CYP2C19 genotype to guide selection of clopidogrel or ticagrelor in Australia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.